Contrast-enhanced ultrasound of the carotid artery can identify the presence and degree of vascularization in atherosclerotic plaque, providing a noninvasive way to measure the existence and degree of atherosclerosis, according to a recent study.
Contrast-enhanced ultrasound of the carotid artery can identify the presence and degree of vascularization in atherosclerotic plaque, providing a noninvasive way to measure the existence and degree of atherosclerosis, according to a recent study.
Atherosclerotic plaque requires a blood supply from the small capillaries to the outer layers of the large blood vessels such as the carotid artery. Contrast-enhanced ultrasound reveals neovascularization within the plaque and can be used as a surrogate marker for atherosclerosis.
Dr. Steven Feinstein, Falak Shah, and colleagues in the cardiology section of the internal medicine department at Rush University Medical Center in Chicago published their study in the November issue of Vascular Medicine. They describe how they used contrast-enhanced ultrasound to measure atherosclerosis.
They studied 15 patients with a total of 17 significant cases of atherosclerotic carotid artery disease. All patients received contrast-enhanced carotid ultrasound exams before undergoing a carotid endarterectomy. Two patients received bilateral endarterectomies. The ultrasound results were compared with histological studies of carotid plaque samples removed during surgery.
All of the plaque samples were stained with the specific vascular markers CD31, CD34, von Willebrand factor, and hemosiderin to measure the presence and degree of neovascularization.
The contrast-enhanced carotid ultrasound measurements of neovascularization most closely correlated with the measurements obtained from the CD31 stain, with a correlation value of 0.68 using Spearman's rank method. The other vascular markers all produced a correlation value of 0.50.
The researchers concluded that contrast-enhanced carotid ultrasound measurements correlate well with histological measures of neovascularization in atherosclerotic plaque and could be used as a surrogate marker for atherosclerosis. The FDA has not approved use of contrast in ultrasound in the U.S., though it is in use in Europe and other regions.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.